FIHL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Fidelis Insurance Holdings Ltd is not a strong buy for a beginner long-term investor at this time. Despite positive technical indicators and hedge fund buying activity, the company's recent financial performance is poor, with significant declines in revenue, net income, and EPS. Additionally, analysts' ratings are mixed, and the stock is overbought based on RSI. Given the investor's preference for long-term growth and the lack of strong positive catalysts, it is advisable to hold off on purchasing this stock for now.
The stock shows bullish technical indicators with a positive MACD histogram (0.132), bullish moving averages (SMA_5 > SMA_20 > SMA_200), and a current price above key resistance levels (R1: 20.199). However, the RSI of 83.649 indicates the stock is overbought, suggesting limited immediate upside potential.
Hedge funds are significantly increasing their positions in the stock, with a 244.72% increase in buying activity over the last quarter. Analysts have raised price targets recently, with some maintaining Buy or Outperform ratings.
The company's financial performance in Q4 2025 was weak, with revenue dropping by 12.04% YoY, net income declining by 196.40% YoY, and EPS falling by 207.34% YoY. The stock is overbought based on RSI, and there is a high probability of short-term price declines (-1.05% in the next day, -1.45% in the next week, -2.79% in the next month).
In Q4 2025, Fidelis Insurance experienced a significant decline in financial metrics. Revenue dropped to $598.6 million (-12.04% YoY), net income fell to $117.8 million (-196.40% YoY), and EPS decreased to 1.17 (-207.34% YoY). Gross margin remained flat at 0%.
Analysts have mixed opinions on the stock. Barclays raised the price target to $21 but noted sluggish premium and broker organic growth. UBS and Keefe Bruyette are more optimistic, with price targets of $25 and $26.50, respectively, and Buy or Outperform ratings. However, Goldman Sachs maintains a Sell rating with a price target of $17.50.
